Acalabrutinib received FDA approval in October 2017 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [1].
When is acalabrutinib's patent expected to expire?
The patent for acalabrutinib is complex, with multiple patents covering different aspects of the drug, including composition of matter, methods of use, and formulations. Based on available information from DrugPatentWatch.com, the earliest anticipated patent expiry for acalabrutinib is in 2031, though later expiring patents extend further [2].
What other conditions is acalabrutinib approved for?
Beyond mantle cell lymphoma, acalabrutinib has gained approval for other indications. It is also approved for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [1].
How does acalabrutinib work?
Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. It works by irreversibly binding to BTK, a protein that plays a crucial role in the development and survival of B-cells, including malignant B-cells [1]. By inhibiting BTK, acalabrutinib disrupts signaling pathways essential for B-cell proliferation and survival.
What are the potential side effects of acalabrutinib?
Common side effects associated with acalabrutinib treatment include diarrhea, fatigue, headache, muscle and joint pain, bruising, and cough [1]. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider.
Are there generic versions of acalabrutinib available or in development?
As of now, acalabrutinib is still protected by patents. The development and approval of generic versions, or biosimilars, typically follow the expiration of key patents [2]. The timeline for generic availability will depend on the specific patent landscape and any potential legal challenges.
What is the difference between acalabrutinib and other BTK inhibitors?
Acalabrutinib is considered a second-generation BTK inhibitor. While it targets the same enzyme as first-generation inhibitors like ibrutinib, acalabrutinib is designed for greater selectivity and has shown a different safety profile in clinical trials, with some studies suggesting a potentially lower incidence of certain side effects [3].
Who manufactures acalabrutinib?
Acalabrutinib is manufactured by AstraZeneca [1].
What clinical trials have supported acalabrutinib's approval?
The FDA approval of acalabrutinib was based on data from clinical trials that demonstrated its efficacy and safety in patients with MCL and CLL/SLL. For MCL, the approval was supported by a trial showing significant improvement in progression-free survival compared to placebo in previously treated patients [1].
What are the treatment goals when using acalabrutinib?
The primary goals of acalabrutinib treatment are to control the progression of the lymphoma or leukemia, improve symptoms, and enhance the quality of life for patients [1].
What are the risks associated with stopping acalabrutinib treatment?
Discontinuing acalabrutinib treatment may lead to a return or worsening of the underlying disease, mantle cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma [1].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/acalabrutinib-calquence
[2] https://drugpatentwatch.com/p/acalabrutinib
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773981/